Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD). Patients with newly or relapsed MM obtaining at least minor response after 6 ThaDD courses, were randomised to receive α-interferon (IFN) 3 MU 3 times a week or thalidomide 100 mg daily until relapse. Both groups also received pulsed dexamethasone 20 mg 4 d a month. Fifty-one patients were randomized in the IFN-dexamethasone (ID) arm and 52 in the thalidomide-dexamethasone (TD) arm. The characteristics of two groups were similar. A significantly better 2-years progression-free survival (PFS; 63% vs. 32%; P = 0·024) and overall survival (84% vs. 68%; P = 0·030) was observed in the thalidomide arm. In high-risk patients and in those achieving less than very good partial response after induction, TD fared better in term of PFS. Main side effects were peripheral neuropathy and constipation in TD group, fatigue, anorexia and haematological toxicity in ID arm. There was a 21% probability of discontinuation at 3 years in the thalidomide arm and 44% in the IFN arm (P = 0·014). Low-dose thalidomide plus pulsed low-dose dexamethasone after conventional thalidomide combination-based therapy was also feasible in the long term, enabling significantly better residual disease control if compared with a standard maintenance therapy.

References

Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T.B., Lakhal, A., Romdhane, N.B., Omri, H.E., Elloumi, M., Belaaj, H., Jeddi, R., Aissaoui, L., Ksouri, H., Hassen, A.B., Msadek, F., Saad, A., Hsairi, M., Boukef, K., Amouri, A., Louzir, H., Dellagi, K. & Abdeladhim, A.B. (2008) Single autologous stem-cell transplantationfollowed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood, 11, 1805–1810.
10.1182/blood-2007-07-101212
CAS Web of Science® Google Scholar
Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hu, C., Benboubker, L., Yacoub Agha, I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Louseau, H., Moreau, P. & Facon, T. (2006) Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood, 108, 3289–3294.
10.1182/blood-2006-05-022962
CAS PubMed Web of Science® Google Scholar
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., Van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021–1030.
10.1056/NEJMoa053583
CAS PubMed Web of Science® Google Scholar
Brinker, B.T., Waller, E.K., Leong, T., Heffner, L.T. Jr, Redei, I., Langston, A.A. & Lonial, S. (2006) Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer, 106, 2171–2180.
10.1002/cncr.21852
CAS PubMed Web of Science® Google Scholar
Cunningham, D., Powles, R., Malpas, J., Raje, N., Milan, S., Viner, C., Montes, A., Hicksh, T., Nicolson, M., Johnson, P., Treleaven, J., Raymond, J. & Gore, M. (1998) A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. British Journal of Haematology, 102, 495–502.
10.1046/j.1365-2141.1998.00795.x
CAS PubMed Web of Science® Google Scholar
Feyler, S., Rawstron, A., Jackson, G., Snowden, J.A., Cocks, K. & Johnson, R.J. (2007) Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase II study. British Journal of Haematology, 139, 429–433.
10.1111/j.1365-2141.2007.06817.x
CAS PubMed Web of Science® Google Scholar
Fritz, E. & Ludwig, H. (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Annals of Oncology, 11, 1427–1436.
10.1023/A:1026548226770
CAS PubMed Web of Science® Google Scholar
Mihelic, R., Kaufman, J.L. & Lonial, S. (2007) Maintenance therapy in multiple myeloma. Leukemia, 21, 1150–1157.
10.1038/sj.leu.2404633
CAS PubMed Web of Science® Google Scholar
Offidani, M., Corvatta, L., Piersantelli, M.-N., Visani, G., Alesiani, F., Brunori, M., Galieni, P., Catarini, M., Burattini, M., Centurioni, R., Ferranti, M., Rupoli, S., Scortichini, A.R., Giuliodori, L., Candela, M., Capelli, D., Montanari, M., Olivieri, A., Poloni, A., Polloni, C., Marconi, M. & Leoni, P. (2006a) Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood, 108, 2159–2164.
10.1182/blood-2006-03-013086
CAS PubMed Web of Science® Google Scholar
Offidani, M., Corvatta, L., Marconi, M., Visani, G., Alesaini, F., Brunori, M., Galieni, P., Catarini, M., Burattini, M., Centurioni, R., Rupoli, S., Scortechini, A.R., Giuliodori, L., Candela, M., Capelli, D., Montanari, M., Olivieri, A., Piersantelli, M.-N. & Leoni, P. (2006b) Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenyter, phase II study. Haematologica, 91, 133–136.
CAS PubMed Web of Science® Google Scholar
Sahebi, F., Spielberger, R., Kogut, N.M., Fung, H., Falk, P.M., Parker, P., Krishnan, A., Rodriguez, R., Nakamura, R., Nademanee, A., Popplewell, L., Frankel, P., Ruel, C., Tin, R., Ilieva, P., Forman, S.J. & Somio, G. (2006) Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant patients with multiple myeloma. Bone Marrow Transplantation, 37, 825–829.
10.1038/sj.bmt.1705339
CAS PubMed Web of Science® Google Scholar
Salmon, S.E., Crowley, J.J., Balcerzak, S.P., Roach, R.W., Taylor, S.A., Rivkin, S.E. & Samlowski, W. (1998) Interferon versus interferon plus prednidone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 16, 890–896.
10.1200/JCO.1998.16.3.890
CAS PubMed Web of Science® Google Scholar
San-Miguel, J., Harousseau, J.L., Joshua, D. & Anderson, K.C. (2008) Individualizing treatment of patients with myeloma in the era of novel agents. Journal of Clinical Oncology, 26, 2761–2766.
10.1200/JCO.2007.15.2546
CAS PubMed Web of Science® Google Scholar
Spencer, A., Prince, H.M., Roberts, A., Bradstock, A. & Prosser, I. (2007) Thalidomide improves survival when used following ASCT. Haematologica, 92, 41.
Web of Science® Google Scholar
Stewart, A.K., Chen, C.I., Howson-Jan, K., White, D., Roy, J., Kovacs, M.J., Shustik, C., Sadura, A., Shepherd, L., Ding, K., Meyer, R.M. & Belch, A.R. (2004) Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clinical Cancer Research, 10, 8170–8176.
10.1158/1078-0432.CCR-04-1106
CAS PubMed Web of Science® Google Scholar
The Myeloma Trialists’ Collaborative Group. (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology, 113, 1020–1034.
10.1046/j.1365-2141.2001.02857.x
PubMed Web of Science® Google Scholar
Yakoub-Agha, I., Doyen, C., Hulin, C., Marit, G., Voilat, L., Grosbois, B., Harosseau, J., Duguet, C., Zerbib, R., Facon, T. & Mary, J. (2006) A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: result of a final analysis of the IFM 01-02 study. Journal of Clinical Oncology, 24, 7520.
Google Scholar

Citing Literature

Volume144, Issue5

March 2009

Pages 653-659

Thalidomide-dexamethasone versus Interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Thalidomide-dexamethasone versus Interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study

Summary

References

Citing Literature

References

Related

Information